Last reviewed · How we verify
NCT04940065
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen
trial testing Kesimpta in Relapsing-remitting Multiple Sclerosis in 367 participants. Completed in 12 December 2024.
12 December 2024
Quick facts
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 367 |
| Start date | 30 June 2021 |
| Primary completion | 12 December 2024 |
| Estimated completion | 12 December 2024 |
| Sites | 103 locations across Japan |
Drugs / interventions tested
- Kesimpta (OFATUMUMAB) — full drug profile →
Conditions studied
- Relapsing-remitting Multiple Sclerosis — all drugs for Relapsing-remitting Multiple Sclerosis →
- Active Secondary Progressive Multiple Sclerosis — all drugs for Active Secondary Progressive Multiple Sclerosis →
Sponsor
Novartis Pharmaceuticals — full company profile →
Who can join
Adults 0 to 99, any sex, with Relapsing-remitting Multiple Sclerosis or Active Secondary Progressive Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04940065
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Kesimpta
Trials testing the same drug.
- NCT05634967 — Kesimpta (Ofatumumab) Pregnancy Registry · recruiting
- NCT05334472 — A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for · completed
Other recruiting trials for Relapsing-remitting Multiple Sclerosis
Currently open trials in the same condition.
- NCT05758831 — RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. · Phase 3 · recruiting
- NCT05755061 — WEBCAMS: Walking Exercise for Brain and Cognition in Adults With Multiple Sclerosis · Phase 1 · active not recruiting
- NCT06586177 — Understanding the 'Durable Effect' Concept of B-cell Modulating Therapies · recruiting
Other Novartis Pharmaceuticals trials
Trials by the same sponsor.
- NCT07498335 — Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary · Phase 3 · not yet recruiting
- NCT07489573 — Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa · Phase 4 · not yet recruiting
- NCT07484269 — PULSE Registry: for Patients Receiving Lutetium (177Lu) Vipivotide Tetraxetan · not yet recruiting
- NCT07416162 — A Study of Iptacopan in Korean Patients With Paroxysmal Nocturnal Hemoglobinuria or C3 Glomerulopathy · not yet recruiting
- NCT07387926 — Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+ · Phase 1, PHASE2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04940065 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Novartis Pharmaceuticals
- Last refreshed: 28 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04940065.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing